Product Information
CYCLOSPORINE 0.05% EYE EMULSION is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.9094 per EA under NDC 00378876091. Its NADAC has been published 216 times since Aug 17, 2022.
FDA first approved this application on Feb 2, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.5 mg/mL
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378876091
Classification
Generic
Dosage Form
EMULSION
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
CYCLOSPORINEApproval Type
Generic (ANDA)
FDA Application
ANDA205894FDA Approved
2/2/2022
TE Code
AB
On Market Since
2/3/2022
Pharmacological Classes
Price Statistics
The NADAC for CYCLOSPORINE 0.05% EYE EMULSION has been published 216 times since Aug 17, 2022, and over the history we have for it it has declined 84.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9094 per EA |
|---|---|
| All-time high | $5.9849 (Sep 14, 2022) |
| All-time low | $0.9094 (Sep 23, 2026) |
| 52-week high | $2.0310 |
| 52-week low | $0.9094 |
| Median price | $2.3080 |
| Average price | $2.6414 |
| Largest weekly change | +38.1% (Aug 21, 2024) |
| Weeks tracked | 216 |
| Tracking since | Aug 17, 2022 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
cyclosporine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CYCLOSPORINE 0.05% EYE EMULSION?
The current National Average Drug Acquisition Cost (NADAC) for CYCLOSPORINE 0.05% EYE EMULSION, manufactured by Mylan Pharmaceuticals Inc., is $0.9094 per EA (NDC 00378876091), effective Sep 30, 2026.
How has the price of CYCLOSPORINE 0.05% EYE EMULSION changed over time?
Over the history we have for it, the NADAC for CYCLOSPORINE 0.05% EYE EMULSION has declined 84.8%. It has been tracked across 216 weekly CMS publications since Aug 17, 2022.
What are the highest and lowest recorded NADAC prices for CYCLOSPORINE 0.05% EYE EMULSION?
Since Aug 17, 2022, the NADAC for CYCLOSPORINE 0.05% EYE EMULSION has ranged from a low of $0.9094 (Sep 23, 2026) to a high of $5.9849 (Sep 14, 2022), with a median of $2.3080 per EA.
Are there cheaper alternatives to CYCLOSPORINE 0.05% EYE EMULSION?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CYCLOSPORINE 0.05% EYE EMULSION in a comparable dosage form, but none are currently priced below it.
Who manufactures CYCLOSPORINE 0.05% EYE EMULSION?
CYCLOSPORINE 0.05% EYE EMULSION (NDC 00378876091) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.